Checkpoint inhibitors (CPIs) like pembrolizumab (anti-PD-1), nivolumab (anti-PD-1), and ipilimumab (anti-CTLA-4), work by blocking these proteins, thereby allowing immune cells (particularly T-cells) to recognize and attack cancer cells more effectively. Here, CTLA4 is linked to cancer.